| Study | n | Disease duration (months) | Age (years) | % Female | % RF+ |
| Adalimumab + MTX | |||||
| Weinblatt, 200316 | 67 | 12.2 (1.4) | 57.2 (1.4) | 74.6 | |
| Furst, 200318 | 318 | 9.3 (0.49) | 55 (0.72) | 79.6 | 63.4 |
| Keystone, 200417 | 207 | 11.0 (0.64) | 56.1 (0.94) | 76.3 | 81.6 |
| DREAM study | 186 | 9.6 (0.63) | 55.4 (0.93) | 66.9 | 80.1 |
| Adalimumab mono | |||||
| Van de Putte, 200319 | 70 | 10.0 (0.84) | 52.6 (1.4) | 87 | 91 |
| Van de Putte, 200420 | 113 | 10.6 (0.65) | 52.7 (1.3) | 79.6 | 79.6 |
| DREAM study | 31 | 13.7 (1.9) | 56.0 (2.1) | 76.3 | 81.6 |
| Etanercept + MTX | |||||
| Weinblatt, 199910 | 59 | 13 | 48 | 90 | 84 |
| Lan, 200411 | 29 | 47.6 | 83 | ||
| DREAM study | 171 | 9.0 (0.77) | 55.0 (1.1) | 69.1 | 74.7 |
| Etanercept mono | |||||
| Moreland, 19974 | 44 | 80% >5 years | 52 | 82 | |
| Moreland, 199912 | 78 | 11 | 53 | 74 | 79 |
| Keystone, 200413 | 153 | 8.2 | 52 | 79 | 64 |
| DREAM study | 45 | 9.4 (1.0) | 55.7 (1.8) | 76.3 | 76.3 |
| Infliximab + MTX | |||||
| Maini, 199814 | 15 | 12.1 (2.3) | 58.9 (2.6) | 67 | 66.7 |
| ATTRACT, 99-0415* | 86 | 8.4 (0.7–45) | 56 (25–74) | 70 | 72 |
| DREAM study | 103 | 9.6 (0.9) | 58.3 (1.2) | 67.9 | 76.4 |
DREAM, Dutch Rheumatoid Arthritis Monitoring; MTX, methotrexate; RCT, randomised controlled trial; RF, rheumatoid factor.
Data are presented as means and SE where possible.
*Median values and ranges.